Tempus AI

TEM

Market cap $13.9B

Two Ark Invest ETFs added Tempus AI stock to their holdings last Friday. A BTIG analyst sees significant upside to Tempus AI stock.

TEM's surging Insights revenues, new contracts and expanded AI capabilities highlight its shift toward scalable data-driven growth.

Tempus AI posts its first positive adjusted EBITDA while Butterfly Network pushes revenue gains and efficiency in a rapidly evolving health tech market.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET. The live webcast will be available through the events page of Tempus' Investor Relations website or by clicking the following link: https://ev.

TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.

Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisition, though organic growth in oncology and data licensing remains robust. The precision medicine company landed another $150 million in data licensing contracts.

Cathie Wood added to her stakes in Circle Internet Group, Bitmine Immersion, and Tempus AI on Thursday. The three stocks fell as much as 10% on Thursday, giving Ark Invest a chance to add on a dip.

Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL), marking Tempus' first study collaboration with a non-pr.

Tempus AI, Inc. ( TEM ) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. Welcome back, everyone, to the 2025 Stifel Healthcare Conference.